Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.75 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759418 | 1.00 | GBA1 (0.75) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL1190716 | 1.00 | GBA1 (0.75) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL14759416 | 1.00 | GBA1 (0.75) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL13382323 | 0.91 | GBA1 (0.65) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL3272623 | 0.91 | GBA1 (0.65) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL14964700 | 0.91 | GBA1 (0.69) | GBA1FUCA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL500739 | 0.89 | GBA1 (0.82) | GBA1FUCA1 | |
| SCHEMBL4528469 | 0.89 | GBA1 (0.82) | GBA1FUCA1 | |
| SCHEMBL500738 | 0.89 | GBA1 (0.82) | GBA1FUCA1 | |
| SCHEMBL4094892 | 0.88 | GBA1 (0.65) | GBA1FUCA1SIGMAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025052278-A1 | PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2025-03-13 | — | — | WO | disclosed |
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024109688-A1 | PYRROLE FUSED RING DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 成都百裕制药股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4271676-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | Bionova Pharmaceuticals (Shanghai) Limited (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116829559-A | Carbonyl substituted diazaspiro compounds and uses thereof | 烨辉医药科技(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
| EP-2567951-B1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| US-20130129811-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-05-23 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| US-20130108685-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| EP-2567951-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-2567952-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-2430019-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| WO-1993003026-A1 | NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | GBA1 443/4885FUCA1 512/4885SIGMAR1 3043/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | GBA1 290/4885FUCA1 1874/4885SIGMAR1 3631/4885 |
| US-20130108685-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | GBA1 407/4885FUCA1 2459/4885SIGMAR1 143/4885 |
| US-20130129811-A1 | CATIONIC LIPID | ACOX3, LPCAT1, ACOX1 | GBA1 509/4885FUCA1 3258/4885SIGMAR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.